Canada Markets open in 2 hrs 2 mins

Agile Therapeutics, Inc. (AGRX)

NasdaqCM - NasdaqCM Real Time Price. Currency in USD
Add to watchlist
2.4100+1.1400 (+89.76%)
At close: 04:00PM EDT
2.0100 -0.40 (-16.60%)
Pre-Market: 07:28AM EDT
Full screen
Trade prices are not sourced from all markets
Previous Close1.2700
Open1.6700
Bid0.0000 x 3100
Ask0.0000 x 3000
Day's Range1.6200 - 2.8199
52 Week Range1.0900 - 56.0000
Volume252,519,739
Avg. Volume5,430,955
Market Cap292.564M
Beta (5Y Monthly)1.11
PE Ratio (TTM)N/A
EPS (TTM)N/A
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
  • Motley Fool

    Agile Therapeutics (AGRX) Q1 2022 Earnings Call Transcript

    Before we start, let me remind you that today's call will include forward-looking statements based on current expectations, including statements concerning our financial outlook and financing prospects for the future; our outlook for the second quarter of 2022, management's expectations for our future financial and operational performance, including our expectations regarding the growth of Twirla; our business strategy and our assessment of the combined hormonal contraceptive market, among other statements regarding our plans, prospects and expectations. Such statements represent our judgments as of today, are not promises or guarantees, and may involve risks and uncertainties that may cause actual results to differ from the results discussed in the forward-looking statements. Joining me on today's call are Al Altomari, Agile Therapeutics' chairman and chief executive officer; and Dennis Reilly, chief financial officer.

  • Motley Fool

    Agile Therapeutics (AGRX) Q4 2021 Earnings Call Transcript

    Hello, everyone, and welcome to today's conference call to discuss our fourth quarter and full year 2021 financial results and corporate update. Before we start, let me remind you that today's call will include forward-looking statements based on current expectations, including statements concerning our financial outlook for the future, our outlook for the first quarter of 2022, management's expectations for our future financial and operational performance, our business strategy and our assessment of the combined hormonal contraceptive market, among other statements regarding our plans, prospects and expectations.

  • Zacks

    Agile Therapeutics (AGRX) Reports Q4 Loss, Misses Revenue Estimates

    Agile Therapeutics (AGRX) delivered earnings and revenue surprises of -17.65% and 3.87%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?